Cebiotex
Why do we like Cebiotex?
Problem
Pediatric oncology faces a significant challenge: the lack of advanced, targeted treatments for children with solid cancerous tumors. Pharmaceutical companies often deprioritize pediatric drug development due to limited commercial incentives, leaving young patients with outdated therapies that cause severe side effects and high relapse rates. Post-surgical tumor beds remain a critical area for intervention to prevent recurrence.
Solution
Cebiotex has developed a patented technological platform to create innovative Local Drug Delivery Systems for pediatric oncology. Their first candidate, CEB-01, is a textile membrane made of nanofibers (PLGA) loaded with SN-38 (an active metabolite of Irinotecan). Applied directly to the surgical site, it delivers targeted chemotherapy, reducing systemic toxicity and improving treatment effectiveness.
Impact
Increase survival rates and reduce relapses in children diagnosed with aggressive cancers.